Terbinafine has activity against some Candida species but not others, and it is not approved or commonly prescribed for most Candida infections. It works well against dermatophytes (the fungi behind athlete’s foot, ringworm, and nail fungus), and while lab studies show it can inhibit certain Candida strains, its real-world use for yeast infections is limited and mostly off-label.
How Terbinafine Works Against Fungi
Terbinafine kills fungi by blocking an enzyme called squalene epoxidase, which fungi need to build their cell membranes. Without this enzyme, a toxic substance (squalene) builds up inside the fungal cell while the membrane loses a critical structural component called ergosterol. For most fungi, this combination is lethal.
Candida responds somewhat differently. In Candida albicans, terbinafine doesn’t kill the cells outright the way it does with dermatophytes. Instead, it slows growth by starving the yeast of ergosterol. This makes terbinafine fungistatic (growth-inhibiting) rather than fungicidal (cell-killing) against Candida albicans, which is a meaningful distinction when you’re trying to clear an active infection.
Which Candida Species Respond to Terbinafine
Lab testing of 259 clinical Candida isolates shows a clear split between species that are susceptible and species that are essentially resistant:
- Candida parapsilosis: Highly susceptible. Terbinafine inhibited 90% of isolates at a very low concentration (0.125 μg/ml), making this the most responsive species.
- Candida albicans: Moderately susceptible. Half of isolates were inhibited at 1 μg/ml, though some strains required much higher concentrations. For comparison, fluconazole inhibited half of the same isolates at 0.5 μg/ml, meaning it was roughly twice as potent.
- Candida lusitaniae and Candida dubliniense: Showed some susceptibility in limited testing.
- Candida glabrata, Candida krusei, and Candida tropicalis: Effectively resistant. These species required concentrations above 128 μg/ml, far beyond what oral or topical terbinafine can deliver in the body.
This matters because Candida glabrata and Candida tropicalis are increasingly common causes of yeast infections, particularly in people who have had recurrent infections or prior antifungal treatment. If your infection involves one of these species, terbinafine will not help.
What Terbinafine Is Actually Approved For
The FDA approves oral terbinafine (Lamisil) for one condition: fungal nail infections caused by dermatophytes. Over-the-counter topical terbinafine is marketed for athlete’s foot, jock itch, and ringworm. None of these approvals cover Candida infections of any type.
Any use of terbinafine for a Candida infection is off-label, meaning a doctor is prescribing it outside its intended use based on their clinical judgment. This isn’t inherently wrong, but it means the evidence supporting it is thinner than for approved antifungals like fluconazole or clotrimazole.
Evidence for Vaginal Yeast Infections
One small clinical trial tested 1% terbinafine vaginal cream in 25 women with vulvovaginal candidiasis. After two weeks, 76% were completely cured, 20% showed a moderate response and needed a third week of treatment, and 4% (one patient) didn’t respond and was switched to fluconazole. After just one week, 88% showed a meaningful response. The researchers suggested terbinafine cream could work as a first-line treatment.
However, this was a small, single study. Clotrimazole and fluconazole remain the standard treatments for vaginal yeast infections, backed by decades of larger trials. Terbinafine cream for vaginal use isn’t widely available or recommended in clinical guidelines.
Evidence for Oral and Esophageal Thrush
Oral terbinafine is not recommended for oral or esophageal candidiasis. Very little clinical data exists for these infections. The one notable finding is a case report showing that combining oral terbinafine with fluconazole successfully treated fluconazole-resistant oral thrush, suggesting terbinafine may have a role as a backup in combination therapy rather than as a standalone treatment.
Terbinafine Combined With Other Antifungals
The most promising use of terbinafine against Candida may be in combination with azole antifungals like fluconazole. Lab studies consistently show synergy between the two drug classes against Candida albicans and other fungal pathogens. The logic is straightforward: terbinafine and azoles block two different steps in the same pathway that fungi use to build their cell membranes. Hitting both steps simultaneously makes it much harder for the fungus to survive.
This combination approach is sometimes used for resistant or refractory fungal infections that haven’t responded to standard treatment. It’s not a first-line strategy, but it gives doctors an option when conventional antifungals fail.
Liver Safety With Oral Terbinafine
If you’re considering or currently taking oral terbinafine, liver health is worth knowing about. The drug’s label warns about potential liver injury, and guidelines recommend liver function testing before starting treatment and periodically during therapy. An analysis of 173 reported cases of terbinafine-related liver injury found that symptoms typically appeared around 33 days after starting the medication, with a range of 5 to 84 days. Serious outcomes were rare but included three deaths and three liver transplants across all published reports.
Some researchers have questioned whether routine monitoring actually catches problems early enough to matter, but most prescribing guidelines still recommend it. If you develop unusual fatigue, nausea, dark urine, or yellowing of the skin while taking oral terbinafine, those are signs to contact your prescriber promptly.
The Bottom Line on Terbinafine and Candida
Terbinafine has real antifungal activity against certain Candida species, particularly Candida parapsilosis and to a lesser extent Candida albicans. But it is not effective against several other common Candida species, and it is not approved or routinely recommended for yeast infections of any kind. Standard antifungals like fluconazole and clotrimazole remain more reliable choices for most Candida infections. Where terbinafine may play a role is in combination therapy for resistant infections or in specific situations where other antifungals can’t be used.